Professor Syed Hussain
Profiles

Professor Syed Hussain

Chair in Oncology

Institute of Translational & Stratified Medicine (Faculty of Medicine and Dentistry)

Role

Professor Syed A Hussain, MBBS, MSc, MD, FRCP

Professor and Chair in Oncology, Consultant in Medical Oncology. Plymouth University, Peninsula Schools of Medicine and Dentistry   

 

"Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He then completed his Medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in Medical oncology.

He is Professor/ Chair and Consultant in Oncology at the University of Plymouth and Plymouth University Hospitals. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up a large number of clinical trials from early phase to late phase studies during his career thus providing early access to novel drugs for patients within the region and receives patient referrals from far and wide.    

 

His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001), to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. His work on split dose cisplatin in bladder cancer has extended the spectrum of patients receiving cisplatin based chemotherapy (Hussain et al BJC 2004). Dr Hussain is principal investigator of a number of studies in bladder, prostate and kidney cancers. He is a chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer. He served as chief investigator of various early phase, and translational studies. Dr Hussain received prestigious ASCO merit award for two consecutive years.

 

 Dr Hussain has authored 77 peer-reviewed publications including 4 book chapters in textbooks of oncology. Dr Hussain has been an invited speaker to international and national meetings. Dr Hussain has secured funding of over 3.6 million pounds from national funding bodies.

Key publications are highlighted

Journals
Articles
Perez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G & Durán I 2017 'Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens' European Urology Author Site , DOI PEARL
Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D & Bamias A 2017 'Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a phase 3, open-label, multicentre randomised controlled trial' The Lancet , DOI PEARL
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A & Bamias A 2017 'Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial' The Lancet 390, (10109) 2266-2277 , DOI PEARL
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J & Ladoire S 2017 'Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors' Clinical Genitourinary Cancer 16, (1) e161-e167 , DOI
Jones RJ, Hussain SA, Protheroe AS, Birtle A, Chakraborti P, Huddart RA, Jagdev S, Bahl A, Stockdale A & Sundar S 2017 'Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer' Journal of Clinical Oncology 35, (16) 1770-1777 , DOI
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong Y-N, Viterbo R, Sonpavde G, Harshman LC & Crabb S 2017 'Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study' European Urology Focus , DOI
Al-Jameel W, Gou X, Forootan SS, Al Fayi MS, Rudland PS, Forootan FS, Zhang J, Cornford PA, Hussain SA & Ke Y 2017 'Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5' Oncotarget , DOI PEARL
Hussain S, Palmer D, Syn W-K, Sacco J, Greensmith R, Elmetwali T, Aachi V, Lloyd B, Jithesh P & Arrand J 2017 'Gene expression profiling in bladder cancer identifies potential therapeutic targets' International Journal of Oncology , DOI PEARL
Choudhury A, West CM, Porta N, Hall E, Denley H, Hendron C, Lewis R, Hussain SA, Huddart R & James N 2017 'The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)' British Journal of Cancer 116, (5) 649-657 , DOI
Hussain SA, Ansari J, Huddart R, Power DG, Lyons J, Wylie J, Vilarino-Varlela M, Elander NO, McMenemin R & Pickering LM 2017 'VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland' International Journal of Oncology 50, (3) 768-772 , DOI PEARL
Powles T, Huddart RA, Elliott T, Sarker S-J, Ackerman C, Jones R, Hussain S, Crabb S, Jagdev S & Chester J 2017 'Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer' Journal of Clinical Oncology 35, (1) 48-55 , DOI
Al Fayi MS, Gou X, Forootan SS, Al-Jameel W, Bao Z, Rudland PR, Cornford PA, Hussain SA & Ke Y 2016 'The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance' Oncotarget , DOI PEARL
Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM & Parker C 2016 'Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)' BJU International 119, (4) 522-529 , DOI PEARL
Elander NO & Hussain SA 2016 'PARP Inhibition in Prostate Cancer: A Promising Approach' ONCOLOGY-NEW YORK 30, (5) 393-+ Author Site
Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I & Wimalasingham A 2016 'A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer' European Urology 69, (3) 450-456 , DOI
El-Taji OMS, Alam S & Hussain SA 2016 'Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers' Current Treatment Options in Oncology 17, (3) , DOI PEARL
Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, Al Fayi MS, Al-Jameel W, Rudland PS & Hussain SA 2016 'Fatty acid activated PPAR gamma promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter' ONCOTARGET 7, (8) 9323-9340 Author Site , DOI
Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, Fayi MSA, Al-Jameel W, Rudland PS & Hussain SA 2016 'Fatty acid activated PPAR&#x3B3; promotes tumorigenicity of prostate cancer cells by up regulating <i>VEGF</i> via PPAR responsive elements of the promoter' Oncotarget 7, (8) , DOI PEARL
James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D & O’Sullivan J 2016 'Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both' JAMA Oncology 2, (4) 493-493 , DOI
Nedjadi T, Al-Ammari A, Khayyat D, Salem N, Al-Sayyad A, Hussain SA, Azhar E, Damanhouri G & Al-Maghrabi J 2016 'The cell cycle regulator p27(Kip1) is associated with urothelial bladder cancer invasion' INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 9, (10) 10515-10521 Author Site
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A & Tunariu N 2015 'DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer' New England Journal of Medicine 373, (18) 1697-1708 , DOI
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C & Di Lorenzo G 2015 'Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin' Clinical Genitourinary Cancer 14, (4) 331-340 , DOI
Powles T, Huddart RA, Elliott T, Sarker SJ, Ackerman C, Jones R, Hussain SA, Crabb S, Jagdev S & Chester J 2015 'A phase II/III, double-blind, randomised trial comparing maintenance lapatinib versus placebo after first line chemotheraphy in HER1/2 positive metastatic bladder cancer patients' Journal of Clinical Oncology , DOI
EL-TAJI OMS, KHATTAK AQ & HUSSAIN SA 2015 'Bladder reconstruction: The past, present and future' Oncology Letters 10, (1) 3-10 , DOI
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Powles T, Moshier EL & Ladoire S 2015 'Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer' Cancer 121, (15) 2586-2593 , DOI
Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A & Vaishampayan UN 2015 'Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy' Clinical Genitourinary Cancer 13, (2) 178-184 , DOI
Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera S-Z & Mu S 2014 'A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function' Cancer Chemotherapy and Pharmacology 75, (1) 87-95 , DOI
Hayden A, Douglas J, Sommerlad M, Andrews L, Gould K, Hussain S, Thomas GJ, Packham G & Crabb SJ 2014 'The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer' Urologic Oncology: Seminars and Original Investigations 32, (6) 806-814 , DOI
2014 'Molecular Mechanisms Involved in the Transition of Prostate Cancer Cells from Androgen Dependant to Castration Resistant State' Journal of Andrology and Gynaecology 2, (3) , DOI
Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G & Kagebayashi C 2013 'The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers' Cancer Epidemiology Biomarkers & Prevention 23, (1) 144-153 , DOI
Huddart RA, Hall E, Hussain SA, Jenkins P, Rawlings C, Tremlett J, Crundwell M, Adab FA, Sheehan D & Syndikus I 2013 'Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)' International Journal of Radiation Oncology*Biology*Physics 87, (2) 261-269 , DOI
Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD & Sonpavde G 2013 'Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma' Clinical Genitourinary Cancer 11, (3) 316-320 , DOI
Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ & Ross PJ 2013 'Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom' British Journal of Cancer 109, (4) 888-890 , DOI PEARL
Ansari J, Hussain, Glaholm & Ansari A 2013 'Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma' Biologics: Targets and Therapy 39-39 , DOI PEARL
James ND & Hussain SA 2013 'A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation' American Society of Clinical Oncology Educational Book 33, 200-206 , DOI
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T & Hendron C 2012 'Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer' New England Journal of Medicine 366, (16) 1477-1488 , DOI
Hussain S 2012 'A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer' Oncology Letters , DOI
Bryan RT, Wei W, Shimwell NJ, Collins SI, Hussain SA, Billingham LJ, Murray PG, Deshmukh N, James ND & Wallace DMA 2011 'Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer' PROTEOMICS - Clinical Applications 5, (9-10) 493-503 , DOI
Ma YT, Cullen MH & Hussain SA 2011 'Biology of Germ Cell Tumors' Hematology/Oncology Clinics of North America 25, (3) 457-471 , DOI
Ansari J, A Hussain S, Alhasso A, Mahmood R, Ansari A & Glaholm J 2011 'Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions' Anti-Cancer Agents in Medicinal Chemistry 11, (3) 296-306 , DOI
Hassan MSU, Ansari J, Spooner D & Hussain SA 2010 'Chemotherapy for breast cancer (Review)' ONCOLOGY REPORTS 24, (5) 1121-1131 Author Site , DOI
Ansari J, Glaholm J, McMenemin R, James ND & Hussain SA 2010 'Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma' Anti-Cancer Agents in Medicinal Chemistry 10, (3) 225-235 , DOI
Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS, Hussain S, James N, Wallace DMA & Cheng KK 2010 'The West Midlands Bladder Cancer Prognosis Programme: rationale and design' BJU International 105, (6) 784-788 , DOI
Ansari J, Hussain SA, McMenemin R & Glaholm J 2009 'Re-challenging with Docetaxel chemotherapy following relapse: Is this an effective treatment strategy' Prostate Cancer Forum
Ansari J, Palmer D, Rea D & Hussain S 2009 'Role of Tyrosine Kinase Inhibitors in Lung Cancer' Anti-Cancer Agents in Medicinal Chemistry 9, (5) 569-575 , DOI
Chue AL, Fernando IN, Hussain SA & Yates DA 2009 'Chemotherapy related encephalopathy in a patient with Stage IV cervical carcinoma treated with cisplatin and 5-fluorouracil: a case report' Cases Journal 2, (1) 8526-8526 , DOI PEARL
Hussain SA, Esposito SP & Rubin M 2008 'Identification of Small Bowel Diverticula with Double-Balloon Enteroscopy Following Non-diagnostic Capsule Endoscopy' Digestive Diseases and Sciences 54, (10) 2296-2297 , DOI
Hussain SA, Ma YT, Palmer DH, Hutton P & Cullen MH 2008 'Biology of testicular germ cell tumors' Expert Review of Anticancer Therapy 8, (10) 1659-1673 , DOI
Hussain S, Palmer D, Swinson D, Riley P, Wills A, Brown C, Draycott C, El-Modir A, Peake D & Rea D 2008 'A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting' Oncology Reports , DOI
Hussain SA, Ting Ma Y & Cullen MH 2008 'Management of metastatic germ cell tumors' Expert Review of Anticancer Therapy 8, (5) 771-784 , DOI
Hussain S, Pascoe J, Palmer D, Spooner D & Rea D 2008 'Genomics and Pharmacogenomics in the Management of Breast Cancer' Current Pharmacogenomics and Personalized Medicine 6, (1) 45-55 , DOI
Hussain SA, Rea DW & Palmer DH 2007 'Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX' British Journal of Cancer 96, (8) 1310-1310 , DOI
Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS & Billingham L 2007 'Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer' British Journal of Cancer 96, (1) 104-109 , DOI PEARL
Hussain SA, Palmer DH, Spooner D & Rea DW 2007 'Molecularly Targeted Therapeutics for Breast Cancer' BioDrugs 21, (4) 215-224 , DOI
Hussain S, Rea D, James N & Palmer D 2007 'Signal Transduction Therapy: Challenges to Clinical Trial Design' Current Signal Transduction Therapy 2, (1) 21-30 , DOI
Hussain SA, Palmer DH, Stevens A, Spooner D, Poole CJ & Rea DW 2005 'Role of chemotherapy in breast cancer' Expert Review of Anticancer Therapy 5, (6) 1095-1110 , DOI
Palmer DH, Hussain SA & Johnson PJ 2005 'Gene- and immunotherapy for hepatocellular carcinoma' Expert Opinion on Biological Therapy 5, (4) 507-523 , DOI
Bryan RT, Hussain SA, James ND, Jankowski JA & Wallace DMA 2005 'Molecular pathways in bladder cancer: Part 1' BJU International 95, (4) 485-490 , DOI
Bryan RT, Hussain SA, James ND, Jankowski JA & Wallace DMA 2005 'Molecular pathways in bladder cancer: Part 2' BJU International 95, (4) 491-496 , DOI
James N & Hussain SA 2005 'Management of muscle invasive bladder cancer - British approaches to organ conservation' SEMINARS IN RADIATION ONCOLOGY 15, (1) 19-27 Author Site , DOI
JAMES N & HUSSAIN S 2005 'Management of muscle invasive bladder cancer?British approaches to organ conservation' Seminars in Radiation Oncology 15, (1) 19-27 , DOI
Hussain SA & James ND 2005 'Molecular markers in bladder cancer' SEMINARS IN RADIATION ONCOLOGY 15, (1) 3-9 Author Site , DOI
Hussain SA, Palmer DH, Moon S & Rea DW 2004 'Endocrine therapy and other targeted therapies for metastatic breast cancer' Expert Review of Anticancer Therapy 4, (6) 1179-1195 , DOI
Palmer DH, Hussain SA & Johnson PJ 2004 'Systemic therapies for hepatocellular carcinoma' Expert Opinion on Investigational Drugs 13, (12) 1555-1568 , DOI
Palmer D, Hussain S, Ganesan R, Cooke P, Wallace D, Young L & James N 2004 'CD40 expression in prostate cancer: A potential diagnostic and therapeutic molecule' Oncology Reports , DOI
Hussain SA, Williams S, Stevens A & Rea DW 2004 'Endocrine therapy for early breast cancer' Expert Review of Anticancer Therapy 4, (5) 877-888 , DOI
Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D & James ND 2004 'A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer' British Journal of Cancer 91, (5) 844-849 , DOI PEARL
Okorie M, Hussain S, Riley P & McCafferty I 2004 'The use of self-expandable metal stents in the palliation of malignant bowel obstruction' Oncology Reports , DOI
Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DMA & James ND 2004 'Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer' British Journal of Cancer 90, (11) 2106-2111 , DOI PEARL
Hussain S, Palmer D, Ganesan R, Hiller L, Gregory J, Murray P, Pastorek J, Young L & James N 2004 'Carbonic anhydrase IX, a marker of hypoxia: Correlation with clinical outcome in transitional cell carcinoma of the bladder' Oncology Reports , DOI
Hussain SA & James ND 2003 'The systemic treatment of advanced and metastatic bladder cancer' The Lancet Oncology 4, (8) 489-497 , DOI
Hussain SA, Ganesan R, Hiller L, Murray PG, El-Magraby MM, Young L & James ND 2003 'Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder' British Journal of Cancer 88, (4) 586-592 , DOI PEARL
Hussain SA, Ganesan R, Hiller L, Cooke PW, Murray P, Young LS & James ND 2003 'BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder' ONCOLOGY REPORTS 10, (3) 571-576 Author Site
Simmons J, Hussain S, Riley P & Wallace DM 2003 'Management of renal angiomyolipoma in patients with tuberous sclerosis complex' Oncology Reports , DOI
Hussain SA & James ND 2002 'Organ preservation strategies in bladder cancer' Expert Review of Anticancer Therapy 2, (6) 641-651 , DOI
Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P & Seymour L 2001 'Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954' CLINICAL CANCER RESEARCH 7, (9) 2662-2668 Author Site
Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DMA & James ND 2001 'A phase I—II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer' Annals of Oncology 12, (7) 929-935 , DOI
Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P & Kerr DJ 2001 'Hepatocellular carcinoma' Annals of Oncology 12, (2) 161-172 , DOI
Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW & Kerr DJ 2001 'Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin' Annals of Oncology 12, (2) 245-248 , DOI
Mullholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymour LW & Kerr DJ 2001 'Pharmacokinetics and bioavailability Study of QC12, a water-soluble, prodrug of quercetin' Annals of Oncology 12, (2) 245-248
Hussain SA & James N 2000 'Role of chemotherapy in anal tumours' GI Cancer 3, (3) 181-187
Hassan S, Ansari J, Spooner D & Hussain SA 0 'Advances in chemotheraphy in breast cancer' Oncology Reports 24, 1121-1131
Carr DF, Ayehunie S, Davies A, Duckworth CA, French S, Hall N, Hussain SA, Mellor HR, Norris A & Park BK 0 'Development of better models of mechanistic biomarkers for drug-induced gastrointestinal injury' Pharmacology and Therapeutics 172, 181-194
Chapters
Hussain SA 2013 'Bladder Cancer' Perez & Brady's Principles and Practice of Radiation Oncology Lippincott Williams & Wilkins
James ND & Hussain SA 2013 'A multidisciplinary approach in muscle-invasive disease' American Society of Clinical Oncology, Education Book
Hussain SA 2013 'Systematic chemotherapy for liver tumours' Hepatobiliary Cancer PMPH-USA
Hussain SA 2008 'Concomitant chemo-radiotherapy principles and management' Treatment of Cancer Sikora, Illidge Hodder Education
Conference Papers
von Amsberg G, Perez-Garcia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz M & Niegisch G 2017 'Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy' 115-115
Smith MR, de Bono JS, Sternberg CN, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman AM, Holzer W & De Wit R 2016 'Phase 3 study of cabozantinib in previously treated metastatic castration-resistant prostate cancer (COMET-1)' American Society of Clinical Oncology
Hoffman-Censits JH, Grivas P, Van Der Heijden MS, Dreicer R, Loriot Y, Retz M, Vogelzang NJ, Perez-Gracia JL, Rezazadeh A & Bracarda S 2016 'IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)' 355-355 , DOI
Hussain SA, Khattak AQ, Cornford P, Weston R, Somov P & Jackson R 2016 'Outcome of radical cystectomy series in the management of muscle invasive bladder cancer: Liverpool experience' 396-396 , DOI
Powles T, Hussain SA, Protheroe A, Birtle A, Chakraborti PR, Huddart R, Jagdev S, Bahl A, Stockdale A & Sundar S 2016 'PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours' 430-430 , DOI
Ramos J, Wong Y-N, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J, Golshayan AR & Powles T 2016 'Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT)' 422-422 , DOI
Powles T, Huddart RA, Elliott T, Jones R, Hussain SA, Crabb SJ, Ackerman C, Jagdev S, Chester JD & Hilman S 2015 'A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients'
Harshman LC, Werner L, Wong Y-N, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J & Vaishampayan UN 2015 'Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC)'
Hussain SA, Jackson R, Shields A, Dickinson L, Cornford P, Jones RJ, Lester JF, Chester JD, Birtle AJ & Powles T 2015 'Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer'
Powles T, Wheater MJ, Din O, Geldart TR, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I & Sarker S-J 2015 'A randomized phase II study of AZ2014 versus everolimus in patients with VEGF refractory metastatic clear cell renal cancer (mRCC)' 409-409 , DOI
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C & di Lorenzo G 2015 'Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy' 335-335 , DOI
Hussain SA, Hendron C, Buckley L, Dickinson L, Syndikus I, Malik Z, Eswar C & James ND 2015 'Results of the phase I trial of cetuximab with mitomycin c and 5-fluorouracil concurrent with radiotherapy treatment in patients with muscle-invasive bladder cancer' 368-368 , DOI
Hussain SA, Ansari J, Huddart RA, Wylie J, Vilarino-Varela M, Faust G, Tan M, Lyons J, Hassall A & Escriu C 2015 'VICTOR: Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)—A retrospective analysis of use of Vin in multicenter, real life setting as second-line chemotherapy (ChT) through free-of charge-programme (FOCP) for patients (pts) in the UK' 352-352 , DOI
Galsky MD, Harshman LC, Crabb SJ, Wong Y-N, Yu EY, Chowdhury S, Powles T, Pal SK, Moshier EL & Ladoire S 2014 'Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC)'
Jones RJ, Chester JD, Dixon-Hughes J, Alexander L, Bahl A, Hussain SA, Birtie A, Jagdev S, Morris A & Stobo J 2014 'Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium (PLUTO)'
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR & Ford D 2013 'Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)'
James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI, Daunton A, Birtle AJ, Chakraborti PR & Ford D 2013 'Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)'
Hussain SA, Palmer DH, Syn WK, Sacco JJ, Lloyd B, Jithesh P, Arrand JR, Barton D, Ansari J & Sibson DR 2013 'Gene expression profiling in bladder cancer to identify potential therapeutic targets'
Ansari J, White L, Glen H, McGlynn B, Nairn R, Balsitis M, Hollins G, Smith K, Nair B & Gurun M 2012 'Active surveillance for prostate cancer: Scottish experience' 167-167 , DOI